{"id":46963,"date":"2022-08-04T22:02:02","date_gmt":"2022-08-04T20:02:02","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/schrodinger-reports-second-quarter-2022-financial-results\/"},"modified":"2022-08-04T22:02:02","modified_gmt":"2022-08-04T20:02:02","slug":"schrodinger-reports-second-quarter-2022-financial-results","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/schrodinger-reports-second-quarter-2022-financial-results\/","title":{"rendered":"Schr\u00f6dinger Reports Second Quarter 2022 Financial Results"},"content":{"rendered":"
\n

\nSoftware Revenue of $30.0 Million, a 25 Percent Increase Over Second Quarter of 2021<\/i>; Total Revenue of $38.5 Million, up 29 Percent Over Second Quarter of 2021<\/i>\n<\/p>\n

\nCompany Maintains Full-Year 2022 Financial Outlook<\/i>\n<\/p>\n

\nPhase 1 Clinical Study of SGR-1505, Schr\u00f6dinger\u2019s MALT1 Inhibitor, On-Track to Begin in the Fourth Quarter of 2022<\/i>\n<\/p>\n

NEW YORK–(BUSINESS WIRE)–Schr\u00f6dinger, Inc.<\/a> (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced financial results for the second quarter of 2022.\n<\/p>\n

\n\u201cWe are very pleased with our performance for the quarter and for the first six months of 2022, with both software and drug discovery revenue contributing to strong growth, and our cash position is strong,\u201d stated Ramy Farid, Ph.D., chief executive officer at Schr\u00f6dinger. \u201cAdditionally, we are seeing continued progress across our collaborative and internal drug discovery pipeline. In the second quarter, our investigational new drug application for our MALT1 inhibitor, SGR-1505, was cleared to proceed to Phase 1 clinical development. We are on track to initiate our Phase 1 study of SGR-1505 in patients with relapsed or refractory B-cell lymphoma in the fourth quarter of 2022.\u201d\n<\/p>\n

\nSecond Quarter 2022 Financial Highlights<\/b>\n<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\nThree Months Ended<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\nJune 30,<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n2022<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n2021<\/b>\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n% Change<\/b>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n(in millions)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTotal revenue\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n38.5\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n29.8\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n29\n<\/p>\n<\/td>\n

\n

\n%\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nSoftware revenue\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n30.0\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n24.1\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n25\n<\/p>\n<\/td>\n

\n

\n%\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nDrug discovery revenue\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n8.5\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n5.7\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n48\n<\/p>\n<\/td>\n

\n

\n%\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nGross profit\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n17.1\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n12.0\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n43\n<\/p>\n<\/td>\n

\n

\n%\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nSoftware gross margin\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n76\n<\/p>\n<\/td>\n

\n

\n%\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

\n

\n77\n<\/p>\n<\/td>\n

\n

\n%\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOperating expenses\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n60.6\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n42.3\n<\/p>\n<\/td>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n\n

\n43\n<\/p>\n<\/td>\n

\n

\n%\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nOther income (expense)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n(4.2\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n(4.6\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nNet loss\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n(47.7\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n$\n<\/p>\n<\/td>\n

\n

\n(35.0\n<\/p>\n<\/td>\n

\n

\n)\n<\/p>\n<\/td>\n

<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nAt June 30, 2022, Schr\u00f6dinger had cash, cash equivalents, restricted cash and marketable securities of approximately $513 million, compared to approximately $529 million at March 31, 2022.\n<\/p>\n

\nRecent Company Highlights<\/b>\n<\/p>\n

\nCollaborative Programs and Internal Pipeline<\/i>\n<\/p>\n